Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$13.70

-0.95 (-6.48%)

, GILD

Gilead

$85.46

4.27 (5.26%)

05:46
01/29/18
01/29
05:46
01/29/18
05:46

Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.

IOVA

Iovance Biotherapeutics

$13.70

-0.95 (-6.48%)

GILD

Gilead

$85.46

4.27 (5.26%)

CELG

Celgene

$105.17

0.78 (0.75%)

JUNO

Acquired by CELG

$85.72

-0.03 (-0.03%)

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

  • 30

    May

IOVA Iovance Biotherapeutics
$13.70

-0.95 (-6.48%)

09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.
01/22/18
CHDN
01/22/18
NO CHANGE
Target $30
CHDN
Buy
Iovance Biotherapeutics named a top pick for 2018 at Chardan
Chardan analyst Gbola Amusa has previously highlighted Iovance Biotherapeutics as an underappreciated name in the immuno-oncology space and now names the stock as a top pick for 2018, citing the promise of important datasets in 2018-19 and the transformation of its manufacturing process from a 6-week process to 22 days. Amusa has a Buy rating and $30 price target on Iovance shares.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $22
HCWC
Buy
Iovance Biotherapeutics price target raised to $22 from $16 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Iovance Biotherapeutics to $22 saying last night's preliminary head and neck and cervical data provide "first spark" to his "game changing thesis." These data are an early but encouraging look at efficacy in solid tumors beyond melanoma, Pantginis tells investors in a research note. The analyst believes the equity raise, also announced last night, should provide Iovance with a cash balance of approximately $272M, providing a "comfortable buffer" to drive LN-144 to potential approval in melanoma and "significant" Phase 2 data in several indications. Pantginis keeps a Buy rating on Iovance Biotherapeutics.
GILD Gilead
$85.46

4.27 (5.26%)

01/26/18
JEFF
01/26/18
UPGRADE
Target $95
JEFF
Buy
Gilead upgraded to Buy from Hold at Jefferies
Jefferies analyst Michael Yee upgraded Gilead Sciences to Buy and raised his price target for the shares to $95 from $87. The drugmaker closed yesterday down 11c to $81.19. Gilead "has had it tough since 2015," but he worst is "generally moving behind them," Yee tells investors in a research note. The analyst sees consensus earnings re-growing in 2020 and beyond and three years of declining. He wants to own the stock coming out of the decline and back into the recovery period. Gilead's upcoming 2018 guidance will likely be low for its hepatitis C virus business, and this should not be surprising, Yee contends. At around $80, the analyst thinks the stock's risk/reward "looks good" with upside to $90-$100 if the business stabilizes and the new pipeline plays out to 2019 and beyond.
01/26/18
01/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zillow (Z, ZG) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brad Erickson saying the risk/reward is "too good to pass up" with the stock down 6% since July. 2. Travelers (TRV) upgraded to Neutral from Underweight at Atlantic Equities. 3. Gilead (GILD) upgraded to Buy from Hold at Jefferies with analyst Michael Yee saying Gilead "has had it tough since 2015," but he worst is "generally moving behind them." 4. Whirlpool (WHR) upgraded to Outperform from Market Perform at Raymond James with analyst Sam Darkatsh saying that while EMEA margins were depressed and raw material inflation has expanded further, the next few quarters will be supportive on the prospects of "price hike stickiness, improved washer margins, and conservative guidance". 5. Jack in the Box (JACK) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying that he expects stabilization in same-store sales growth within management's current 1%-2% guidance range given easier year-over-year comparisons starting in the second quarter. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/18
JEFF
01/22/18
NO CHANGE
Target $125
JEFF
Buy
Celgene, Juno deal 'smart' if more than JCAR017 plays out, says Jefferies
Following the announced acquisition of Juno Therapeutics (JUNO) by Celgene (CELG), Jefferies analyst Michael Yee notes that in the short term, the Street will debate whether pivotal Juno data coming will look better than Kite's (GILD) Yescarta and whether JCAR17 is truly differentiated. Longer-term, the analyst believes this is a deal hinged on Celgene's confidence in going "all in" on cell therapy over the next 5-10 years. Like Gilead/Kite, this will be a "smart deal" if more than just JCAR17 plays out, he contends, adding that he thinks it will over next few years. Yee reiterates a Buy rating and $125 price target on Celgene's shares.
01/16/18
SBSH
01/16/18
NO CHANGE
SBSH
Buy
Juno could be worth $110 per share in takeover, says Citi
After the Wall Street Journal reported tonight that Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), Citi analyst Robyn Karnauskas says her analysis indicates Juno could be worth $110 per share in a takeover. The stock in after-hours trading jumped 43%, or $19.50, to $65.10. The analyst, however, points that Kite Pharma had more data at the time of acquisition and was acquired by Gilead Sciences (GILD) for an aggregate price of $11.9B. Karnauskas also notes that Celgene already downs 25% of June's revenues.
CELG Celgene
$105.17

0.78 (0.75%)

01/23/18
LEER
01/23/18
DOWNGRADE
Target $87
LEER
Market Perform
Juno Therapeutics downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Juno Therapeutics (JUNO) to Market Perform from Outperform and raised his price target on the shares to $87 from $56 after Celgene (CELG) announced that it has signed a definitive merger agreement to acquire the company.
01/24/18
LEHM
01/24/18
DOWNGRADE
Target $87
LEHM
Equal Weight
Juno Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Juno Therapeutics (JUNO) to Equal Weight following the proposed acquisition by Celgene (CELG). The analyst believes the offer price of $87 per share fully reflects the value of the stock and sees a low probability of other companies trying to outbid the price. She raised her price target for Juno shares to $87 from $55.
01/23/18
ADAM
01/23/18
NO CHANGE
Target $140
ADAM
Buy
Celgene purchase adds long-term biologics revenues, says Canaccord
Canaccord analyst John Newman said Celgene's (CELG) purchase of Juno (JUNO) gives them access to the CAR-T space and adds $3B in long-term biologics revenues. The analyst also said the company will continue to be open to more acquisitions and sees upside in its pipeline. Newman reiterated his Buy rating and $140 price target on Celgene shares.
01/23/18
RBCM
01/23/18
NO CHANGE
Target $142
RBCM
Top Pick
Celgene price target lowered to $142 from $147 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Celgene (CELG) to $142 but kept his Top Pick rating after the company's announced acquisition of Juno Therapeutics (JUNO) for $9B. The analyst says this deal is an important step toward diversification from the approaching Revlimid patent cliff and should improve sentiment toward further upside in 2018.
JUNO Acquired by CELG
$85.72

-0.03 (-0.03%)

01/24/18
STPT
01/24/18
DOWNGRADE
STPT
Hold
Juno Therapeutics downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Juno Therapeutics (JUNO) to Hold following the takeover by Celgene (CELG).

TODAY'S FREE FLY STORIES

ACN

Accenture

$166.47

-0.47 (-0.28%)

, EADSY

Airbus

$0.00

(0.00%)

04:55
07/21/18
07/21
04:55
07/21/18
04:55
Conference/Events
Farnborough International to hold an airshow »

Farnborough International…

ACN

Accenture

$166.47

-0.47 (-0.28%)

EADSY

Airbus

$0.00

(0.00%)

ATI

Allegheny Technologies

$26.65

0.08 (0.30%)

BAESY

BAE Systems

$0.00

(0.00%)

BDRBF

Bombardier

$0.00

(0.00%)

CAE

CAE

$20.96

0.17 (0.82%)

CW

Curtiss-Wright

$125.79

-0.12 (-0.10%)

DASTY

Dassault Systemes

$0.00

(0.00%)

ESLT

Elbit Systems

$118.98

0.64 (0.54%)

LMT

Lockheed Martin

$322.76

3.09 (0.97%)

BA

Boeing

$354.92

-0.57 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 16

    Aug

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.